venetoclax,posaconazole
abbvie,merck,roche
['aml1718', 'posaconazole', 'leusm', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)']
#ash22 #leusm marconi: treatment cohort schema. posaconazole permitted w 8-fold reduction of ven dose. median age 54, 44% eln high risk. cr/cri 86.7%, cr 70%. higher cr rate in 600mg cohort (ven given for 21d). median followup 10.5mo, so still early to make conclusions re efs/os. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)